News

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical-stage biopharmaceutical ...
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...
The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...
The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. Drug ...
There's one main way to treat inflammatory bowel disease (IBD): Control inflammation by whipping the immune system into shape ...
Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.
News & Observer readers comments on NC’s business ranking, speeding in a Raleigh area, a gun bill, flooding, Thom Tillis, ...
The story behind the development of immune checkpoint inhibitors, fulfilling the promise of cancer immunotherapy ...
Sanofi and Regeneron, AstraZeneca, Roche’s Genentech and GSK have provided support for the Living Well with COPD educational ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio® (mosunetuzumab-axgb) administered subcutaneo ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today its decision to proceed with Phase III development of prasinezumab, an i ...
Here are six new drug shortages and discontinuations, according to drug supply databases from the FDA.